LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Legend Biotech Corp ADR

Open

SectorHealthcare

34.95 12.27

Overview

Share price change

24h

Current

Min

32.2

Max

35.08

Key metrics

By Trading Economics

Income

-140M

-99M

Sales

8.5M

195M

EPS

-0.54

Profit margin

-50.822

Employees

2,700

EBITDA

-141M

-89M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+163.97% upside

Dividends

By Dow Jones

Next Earnings

8 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-551M

5.4B

Previous open

22.68

Previous close

34.95

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Legend Biotech Corp ADR Chart

Past performance is not a reliable indicator of future results.

Related News

13 May 2025, 11:01 UTC

Earnings

Legend Biotech 1Q Loss/Shr 27c >LEGN

13 May 2025, 11:00 UTC

Earnings

Legend Biotech 1Q Rev $195.1M >LEGN

11 Mar 2025, 11:09 UTC

Earnings

Legend Biotech 4Q Research and Development Expenses $104.4M >LEGN

11 Mar 2025, 11:08 UTC

Earnings

Legend Biotech 4Q EPS 7c >LEGN

11 Mar 2025, 11:00 UTC

Earnings

Legend Biotech 4Q Rev $186.5M >LEGN

12 Nov 2024, 12:06 UTC

Earnings

Legend Biotech 3Q Loss/Shr 34c >LEGN

12 Nov 2024, 12:05 UTC

Earnings

Legend Biotech 3Q Net Trade Sales ABout $286M >LEGN

12 Nov 2024, 12:00 UTC

Earnings

Legend Biotech 3Q Rev $160.2M >LEGN

9 Aug 2024, 11:02 UTC

Earnings

Legend Biotech 2Q License Rev Was $90.8M >LEGN

9 Aug 2024, 11:01 UTC

Earnings

Legend Biotech 2Q Collaboration Rev $93.3M >LEGN

9 Aug 2024, 11:01 UTC

Earnings

Legend Biotech 2Q Loss/Shr 5c >LEGN

9 Aug 2024, 11:00 UTC

Earnings

Legend Biotech 2Q Rev $186.5M >LEGN

26 Jul 2024, 11:01 UTC

Earnings

Legend Biotech Expects 2H Adjusted Net Loss $94.7M

Peer Comparison

Price change

Legend Biotech Corp ADR Forecast

Price Target

By TipRanks

163.97% upside

12 Months Forecast

Average 80.14 USD  163.97%

High 95 USD

Low 55 USD

Based on 17 Wall Street analysts offering 12 month price targets forLegend Biotech Corp ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

15

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

30.5 / 33.91Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.